In the quest to control cancer we now face the challenge of translating our increasing insights into the cancer-immunity cycle into more effective immune therapies. In vivo imaging in preclinical models has been instrumental in understanding the complex interactions of cancer and the immune system. The great task now lies in imaging immune responses in real cancer patients in a safe and non-invasive manner, to realise the full potential of immunotherapy in the clinic.
ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced today that it has entered into a non-exclusive license and collaboration agreement with Roche, a leading pharmaceutical company focused on cancer treatment and diagnostics.
ImaginAb, Inc., a clinical stage immuno-oncology imaging company, today announces that it will attend and present at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held June 22-25, 2019, at the Anaheim Convention Center, Anaheim, California.
ImaginAb Inc., a clinical stage immuno-oncology imaging company, announces it has enrolled its first patient for the Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at City of Hope in Los Angeles County.